Prospective Validation of the Prognostic Value of Long Non-coding MFI2-AS1 RNA in Localized Clear Cell Kidney Cancers
NCT ID: NCT04946266
Last Updated: 2022-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
260 participants
OBSERVATIONAL
2021-12-01
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers of Angiogenesis for Response to Therapeutic Combination in Advanced or Metastatic Kidney Cancer
NCT05285579
Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer
NCT00908739
Evaluation of Diagnostic Value of Molecular Markers in Renal Cancer
NCT00491621
Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer
NCT02499458
Evaluation of Fibrin Structure Marker in Cancer Patients Treated and Not Treated With LMWH
NCT02552381
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Surgical intervention
Surgical intervention with collection of tissue material
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Localized kidney tumors\> T1a
* Patient having signed an informed consent
* Patient affiliated to a health insurance plan
* Subject having signed a consent form to participate in research and the constitution of a collection and genetic analyzes
Exclusion Criteria
* Contraindication to performing a TAP CT with injection of contrast product
* Inability to provide informed information about the subject (subject in an emergency situation, difficulties in understanding, etc.)
* Subject under legal protection
* Subject under tutorship or curatorship
* Pregnancy
* Feeding with milk
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Strasbourg, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
TRICARD Thibault
Role: PRINCIPAL_INVESTIGATOR
les Hôpitaux Universitaires de Strasbourg
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Les Hôpitaux Universitaires de Strasbourg
Strasbourg, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
7349
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.